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Abstract   
Despite decades of research, our understanding of the processes controlling the stability of late-
stage atherosclerotic plaques remains poor. However, a prevailing hypothesis is that reducing 
inflammation may improve plaque stability. Indeed, the potent inflammatory cytokine, interleukin (IL)-ȕ
has been shown to be a key driver of atherosclerosis development. Importantly, initial results of the 
CANTOS Trial demonstrated that administration of an anti-IL-ȕDQWLERG\WRKLJK-risk post-myocardial 
infarction (MI) patients did not improve all-cause or overall cardiovascular mortality, only modestly 
reduced the incidence of non-fatal myocardial infarction (MI), and was associated with a 40% increase 
in death by lethal infection. A subsequent CANTOS report showed a 31% reduction in CV mortality and 
all-cause mortality in the subset of CANTOS subjects who achieved on-treatment hsCRP levels of 
<2.0mg/L. However, this patient cohort represents a small fraction of all patients at risk for 
cardiovascular disease, and extensive further investigation is needed to better understand the 
mechanisms by which IL-ȕLQKLELWLRQimpacts established lesions. Therefore, we performed 
intervention studies on smooth muscle cell (SMC) lineage tracing mice with advanced atherosclerosis 
using anti-IL-1E or IgG control antibodies. Surprisingly, we found no effect on lesion size but impaired 
outward remodeling resulting in a decrease in lumen diameter. In addition, there was a profound shift in 
the composition of the fibrous cap characterized by multiple detrimental changes including reduced 
collagen and SMC content but increased macrophage content, which was primarily driven by opposite 
effects on the proliferation of these respective cell types.  By generating SMC-specific and 
macrophage-selective IL-1 receptor type 1 knockout mice (Il1r1 KO) crossed with Apoe-/- mice, we 
found that SMC-specific Il1r1 KO resulted in a ~60% reduction in lesion size and lesions that were 
nearly devoid of YFP+ SMC whereas macrophage-selective loss of IL-1R1 had no effect on lesion size 
or cell composition. This suggests that SMC are a primary cell type responding to IL-1ȕ during 
atherosclerosis and that IL-1 signaling in SMC is critical for their investment and retention within the 
fibrous cap. In addition, we found that inhibition of IL-ȕSURPRWHd an expansion of the M2 macrophage 
population within the fibrous cap, and that these effects may be due in part to elevated levels of IL-4. 
Taken together, our results show that IL-1E can promote beneficial changes in late-stage murine 
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atherosclerosis by promoting maintenance of a SMC/collagen-rich fibrous cap. Moreover, studies 
identify critical cell types and pathways that need to be considered when attempting to develop safer 
and more effective anti-inflammatory therapies for widespread treatment of atherosclerotic disease, 
including in moderate or low risk patients. 
 
 
 
Introduction 
Atherosclerosis is a chronic vascular disease characterized by the formation of plaques 
enriched in lipids and inflammatory cells 1. Despite decades of research, little is known about the 
factors and mechanisms controlling the stability of late-stage atherosclerotic lesions 2. However, human 
pathology studies have consistently shown that the cellular composition of plaques – and most 
importantly of the fibrous cap, a structure that separates the thrombogenic lesion contents from the 
blood – is a critical predictor of plaque rupture. Specifically, plaques with a higher ratio of CD68+ cells 
relative to ACTA2+ cells, presumed to be macrophages 0ĭ and smooth muscle cells (SMC), 
respectively, are more prone to rupture 3-5. Indeed, it has long been assumed that SMC play a 
protective role in atherosclerosis by being the primary cell type responsible for formation of an 
extracellular matrix (ECM)-rich fibrous cap. However, the markers used for identification of the lesion 
cells (e.g., ACTA2 and CD68) are not specific for SMC or 0ĭ during atherosclerosis, which raises 
questions as to the origin of these of cells, and more importantly their functional roles in late-stage 
complications 6. 
 Importantly, results of recent SMC lineage tracing studies from our lab 7,8 and others 9,10 have 
demonstrated that SMC play a much larger role during atherosclerosis than previously appreciated, 
which can be either beneficial or detrimental depending on their phenotypic state. First, we found that 
>80% of SMC-derived cells within advanced lesions lack expression of the conventional SMC marker 
gene, ACTA2. As such, previous studies that relied on using this marker have grossly underestimated 
the frequency of SMC-derived cells within the lesion. Second, nearly 50% of SMC within advanced 
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atherosclerotic lesions express markers of alternative cell types including 0ĭ (ACTA2- MYH11- 
LGALS3+ F4/80+ CD11b+), mesenchymal stem cells (ACTA2- MYH11- SCA1+ CD105+), and 
myofibroblasts (ACTA2+ MYH11- 3'*)ȕ5+) 8,9. Third, contrary to the current dogma, we found that 
SMC can have beneficial or detrimental roles in lesion pathogenesis depending on the nature of their 
phenotypic transitions. For example, Klf4-dependent transitions, including formation of SMC-derived 
MɎ-marker+ foam cells 8 exacerbate lesion pathogenesis whereas Oct4-dependent transitions 7 are 
necessary for the formation of a SMC-rich, protective fibrous cap. Taken together, these results 
highlight the importance of identifying strategies that promote beneficial and/or prevent detrimental (i.e., 
plaque destabilizing) changes in SMC phenotype and function.   
A dominant hypothesis in the field is that excessive inflammation or failed inflammation resolution is a 
major contributor to plaque development as well as late-stage lesion destabilization 11,12. Indeed, there is 
extensive evidence that inflammation promotes atherosclerosis development (reviewed in 13). For example, 
the inflammatory cytokine interleukin-1ȕ (IL-1ȕ) has been shown to play a major role during atherosclerosis 
development using global genetic knockout strategies. Specifically, knockout of IL-ȕ 14 or its functional 
receptor, IL-1 receptor type 1 (Il1r1) 15 reduces plaque formation, whereas knockout of the endogenous 
IL-1 receptor 1 antagonist (IL1ra) increases plaque development 16. In addition, therapeutic inhibition of 
IL-ȕXVLQJD neutralizing antibody (mouse gevokizumab) administered throughout Western diet (WD) 
feeding in Apoe-/- mice showed a reduction in overall plaque burden. However, there was no reduction 
of brachiocephalic artery (BCA) plaque area or increase in lumen area 17. These studies strongly 
implicate IL-1ȕ as a key factor promoting plaque development. However, there are currently no 
preclinical studies showing direct evidence that inhibition of IL-1E after the establishment of advanced 
atherosclerotic lesions induces beneficial changes. Importantly, the CANTOS trial tested three doses (50, 
150, and 300-mg) of an anti-IL-1ȕ antibody, canakinumab, administered quarterly to a very high-risk 
cohort of post-MI patients 18,19. The trial met its primary endpoint (a composite of nonfatal MI, nonfatal 
stroke, and cardiovascular death). However, this occurred only at the 150-mg dose, was driven by a 
reduction in recurrent nonfatal MI but no reduction in the rate of cardiovascular death or stroke, and 
was associated with a 40% increase in deaths due to lethal infection 20. A subsequent CANTOS report 
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showed a 31% reduction in CV mortality and all-cause mortality in the subset of CANTOS subjects who 
achieved on-treatment hsCRP levels of <2 mg/L but no effect in subjects whose hsCRP remained 
above 2 mg/L21. However, the patient cohort tested in CANTOS represents only a small fraction of all 
patients at risk for cardiovascular disease (i.e. those who have survived at least one heart attack and 
have normalized lipids but elevated hsCRP). As such, fundamental questions must be answered before 
canakinumab can be expanded to lower risk patients. What are the key determinants of IL-1Eantibody 
efficacy and safety; were the effects driven by targeting inflammation on a systemic or local level; did 
the therapy protect against plaque erosion, rupture, and/or another thromboembolic mechanism; what 
was the effect on the function of key-cell types within the lesion that regulate late-stage lesion stability? 
As such, there is a critical need for mechanistic studies to define how inhibition of IL-1E impacts late-
stage lesion pathogenesis.  
Despite a clear role for IL-1 signaling in atherosclerosis development, previous studies have not 
clearly defined the key cell types that respond to IL-1ȕ in atherosclerosis. However, two bone marrow 
chimeric studies suggest that IL1 primarily acts on non-hematopoietic cell types during atherosclerosis 
development 22,23. Specifically, transplantation of Il1r1-/- bone marrow into wild-type mice had no effect 
on lesion formation, whereas, transplantation of wild-type bone marrow into Il1r1-/- mice resulted in 
significantly smaller lesions, suggesting that non-hematopoietic cell types including endothelial cells 
(EC) and/or SMC play a key role in mediating IL-1 signaling during atherosclerosis development. 
Interestingly, Sui and co-workers 10 showed that SMC-selective deletion of the Iț% kinase IKK-ȕ, which 
is required for activation of 1)ț%, markedly attenuated lesion development, suggesting a critical role for 
inflammatory signaling in SMC. The latter results are also consistent with several in vitro studies 
identifying IL-ȕ as a potent regulator of SMC migration and proliferation 24-26. However, a direct role of 
IL-1 signaling in SMC during atherosclerosis pathogenesis has not been studied in vivo.  
In the current study, we tested the hypothesis that IL-1E inhibition induces beneficial changes not only 
during fatty streak formation, but also in the setting of established late-stage atherosclerosis. To this end, we 
treated SMC lineage-tracing Apoe-/- mice with a mouse monoclonal anti-IL-1E antibody between 18 and 26 or 
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18 and 21 weeks of WD feeding. Contrary to our expectations, late-stage IL1Eantibody treatment resulted in 
multiple detrimental changes including i) a rapid remodeling of the fibrous cap characterized by reduced 
collagen and SMC content but a large increase in 0ĭ; and ii) no decrease in lesion size but impaired 
beneficial outward vessel remodeling leading to reduced lumen diameter. Equally surprising, we found that 
0ĭ-selective KO of the Il1r1 in Apoe-/- mice had no discernible effects, but SMC-specific Il1r1 KO resulted in 
lesions highly enriched in MɎ relative to SMC with failure to form a SMC-rich fibrous cap. As such, these 
studies reveal an unanticipated role for IL-1ȕ in the formation and maintenance of a protective SMC/collagen-
rich fibrous cap during late-stage lesion atherosclerosis.  
 
 
 
Results 
 
IL-ȕneutralization decreased systemic and local inflammation in advanced atherosclerotic 
lesions 
 Although several studies have previously demonstrated that global disruption of IL-1 signaling 
inhibits lesion development in Apoe-/- mice 14-16, they may not predict the effects of acute inhibition of IL-
ȕ on established atherosclerotic lesions 27. To study the impact of IL-ȕinhibition on advanced 
lesions, we performed intervention studies in which we administered an anti-IL-ȕDQWLERG\PRXVH
monoclonal antibody; 10mg/kg) or an isotype matched IgG control (10mg/kg) for 8 weeks to SMC 
lineage tracing Apoe-/- mice (Apoe-/- Myh11 Cre ERT2 R26R-YFP) that had been fed a WD for 18 weeks 
(Fig 1a; Fig S1a). Mice were fed the same WD during the atherosclerosis lesion development (8 to 26 
weeks of age) and the IL-ȕDQWLERG\WUHDWPHQWWRZHHNVRIDJH SMC lineage tracing Apoe-/- 
mice were treated with tamoxifen between 6 and 8 weeks of age, prior to initiation of WD feeding, to 
permanently label mature MYH11+ SMC and to track their fate and that of their progeny during 
development and progression of atherosclerosis as well as during intervention with an anti-IL1E 
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antibody. We have previously shown that these mice exhibit high efficiency (>95%) of SMC-specific 
labelling by YFP expression when treated with tamoxifen from 6-8 weeks of age 8,28. Treatment with the 
IL-ȕDQWLERG\ potently reduced systemic inflammation including a 50% decrease in the plasma 
concentration of Serum Amyloid-A (SAA) (Fig 1b), and similar reductions in IL-ȕOHYHOVLQSODVPDDQG
liver (Fig 1c). Notably, liver and plasma IL-ĮFRQFHQWUDWLRQVZHUHXQFKDQJHGFig S1b). IL-ȕ
neutralization did not alter body weight or plasma cholesterol and triglyceride levels (Fig S1c-e).  To 
unbiasedly assess the effects of IL-ȕQHXWUDOL]DWLRQLQDWKHURVFOHURWLFOHVLRQV, we performed RNAseq 
analyses on BCA and aortic arch regions from SMC lineage tracing Apoe-/- mice after 8 weeks of 
treatment with the IL-ȕDQWLERG\RUWKH,J*FRQWURO Analysis of transcript expression showed that IL-ȕ 
antibody treatment induced a global reduction in inflammation within lesions as illustrated by the large 
number of downregulated inflammatory pathways (Fig 1d; Fig S2). Interestingly, there was also 
downregulation of cell lineage and cell cycle regulatory pathways. The most upregulated pathways in 
IL-ȕDQWLERG\WUHDWHGPLFHincluded carbohydrate and energy metabolism (Fig 1d). To determine 
whether the antibody had direct neutralizing properties within the lesion, we assessed the IL-ȕ
antibody penetration into atherosclerotic lesions using Rag1 deficient mice which do not produce 
mature T cells and B cells 29. The use of Rag1-/- mice allows for rigorous detection of the mouse 
monoclonal IL-ȕQHXWUDOL]LQJDQWLERG\ZLWKRXWLQWHUIHUHQFHRIHQGRJHQRXVDQWLERGLHV7KH,/-ȕ
antibody was detected at higher levels than the IgG control in atherosclerotic lesions from Rag1-/- Apoe-
/-
 mice fed 26 weeks with WD suggesting a direct effect of the neutralizing antibody within 
atherosclerotic lesions (Fig S1f). Secondly, the local inhibition of the IL-1 signaling pathway was 
confirmed by immunostaining showing a significant decrease in phospho-IRAK and IL-6 in SMC lineage 
tracing Apoe-/- mice treated with the IL-ȕDQWLERG\ as compared to controls (Fig 1e). Taken together, 
these results demonstrate that the IL-ȕDQWLERG\ treatment regimen was effective at inhibiting the IL-1 
signaling pathway, resulting in a decrease in both systemic and local plaque inflammation. 
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Neutralization of IL-ȕ induced multiple unexpected changes in late-stage atherosclerotic 
lesions 
Despite effective inhibition of inflammation, analysis of atherosclerotic plaque burden and BCA 
plaque morphometry showed multiple unexpected results believed to be detrimental for plaque 
pathogenesis. IL-ȕneutralization had no impact on aortic plaque burden (Fig 2a,b) or BCA lesion size 
(Fig 2c,d; Fig S3), but completely inhibited the beneficial outward vessel remodeling that normally 
occurs during plaque expansion (Fig 2c,d; Fig S3). Consequently, IL-ȕDQWLERG\WUHDWHGPLFHhad 
significantly reduced lumen area (Fig 2d). Even more surprising, IL-ȕDQWLERG\WUHDWPHQWUHVXOWHGLQD
profound reduction in YFP+ SMC and increase in YFP-LGALS3+ 0ĭ within the fibrous cap area (Fig 2e; 
Fig S4). This change in cell composition was particularly evident in the fibrous cap area (defined as the 
30µm-thick subluminal area within the lesion which is typically enriched in YFP+ and ACTA2+ cells as 
previously reported 8) (Fig 2f,g; Fig S4b,c). The increase in the LGALS3+ population within the fibrous 
cap area was driven by an increase in the number of non-SMC derived YFP-LGALS3+ 0ĭ (i.e., bone 
marrow-GHULYHGRUUHVLGHQW0ĭZKHUHDVWKHQXPEHURI60&-GHULYHG0ĭ-like cells (i.e., 
YFP+LGALS3+) was unchanged (Fig 2g). However, the proportion of YFP+LGALS3+ cells normalized to 
the total YFP+ SMC population was significantly increased with IL-ȕDQWLERG\WUHDWPHQWFig 2h), 
suggesting that YFP+LGALS3+ cells – in contrast to YFP+ and YFP+ACTA2+ populations – might be 
resistant to loss or clearance following IL-ȕQHXWUDOL]DWLRQ 
The reduction in SMC content was associated with an overall decrease in the ACTA2+ fibrous 
cap thickness (Fig 2i). Moreover, inhibition of IL-ȕDOVRLQGXFHGDsignificant reduction in collagen 
content within the fibrous cap area, a key index of plaque stability (Fig S5b,c). This reduction of 
collagen content within the fibrous cap area could be a direct consequence of the loss of SMC, 
described in previous studies as a major producer of collagen within the lesion 30, but could also be due 
to IL-ȕ-induced upregulation of collagenases. There was no difference in the expression of MMP3 and 
MMP9 (Fig S5d,e), two collagenases known to be regulated by IL-ȕ 31. However, further studies of 
collagenase activity would be required to ascertain the mechanisms by which inhibition of IL-ȕOHDGVto 
collagen loss (i.e., decrease in production and/or increase in degradation). Interestingly, these changes 
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to the fibrous cap area occurred despite having no effect on necrotic core area or intraplaque 
hemorrhage (Fig S5f-h), suggesting that there has not been effective lesion regression or complete 
resolution of lesion inflammation. Moreover, there was no difference in the lesion calcification (Fig 
S6a,b) nor in the proportion of YFP+ SMC expressing RUNX2, a master regulator of SMC osteogenic 
transitions (Fig S6c,d).  
The main features of the IL-ȕLQKLELWLRQdescribed above were also observed when mice were 
treated with a lower dose of the IL-ȕQHXWUDOL]LQJDQWLERG\ (1mg/kg) for 8 weeks (Fig S7a). Treatment 
with the IL-ȕDQWLERG\DWPJNJLQGXFHGa significant, but to a lesser extent, deficit of the beneficial 
outward remodeling (Fig S7b,c) and modification of the cell composition within the fibrous cap area 
including reduced YFP+ SMC and increased LGALS3+ 0ĭ (Fig S7d,e).  
Taken together the preceding results unexpectedly show that IL-ȕ is critical for maintaining a 
SMC/collagen-rich, 0ĭ-poor fibrous cap area. 
 
Macrophage accumulation was driven by local proliferation rather than increased monocyte 
recruitment 
 To better understand the mechanisms responsible for the enrichment of 0ĭ and loss of SMC 
following 8 weeks of IL-ȕ inhibition, we investigated the cell composition after 3 weeks of treatment. 
Apoe-/- Myh11 Cre ERT2 R26R-YFP mice were treated with the IL-ȕDQWLERG\ mg/kg) or the IgG 
control between 18 and 21 weeks of WD feeding (Fig 3a). Remarkably, just 3 weeks of IL-ȕantibody 
treatment resulted in profound changes to the cellular composition of the fibrous cap characterized by 
an increase in the proportion of LGALS3+ cells and reduction in YFP+ SMC (Fig 3b,c). This shift 
reflected a net increase in the number of LGALS3+ cells within the fibrous cap of mice treated with the 
IL-ȕDQWLERG\Fig 3d). The LGALS3+ population was composed predominantly of YFP-LGALS3+ cells, 
whereas the SMC-derived YFP+LGALS3+ population was unchanged (Fig 3e). Furthermore, the 
increase in 0ĭ occurred predominantly in the fibrous cap area (Fig 3b). These data not only support a 
critical role for IL-ȕin maintaining the integrity of the fibrous cap but also reveal that the fibrous cap 
area, as a structure, is much more plastic than previously appreciated. 
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To determine if the increase in LGALS3+ population was driven by increased bone marrow-
derived monocyte recruitment into the plaque, we quantified monocyte influx using a fluorescent latex 
bead trafficking assay 32,33. In brief, Cy3-labeled beads were injected intravenously into Apoe-/- Myh11 
Cre ERT2 R26R-YFP mice one week prior to initiation of antibody treatment (Fig 4a, Fig S8a). Mice 
injected with beads received either the IL-ȕQHXWUDOL]LQJDQWLERG\RU,J*FRQWUROantibody for 3 weeks.  
Flow cytometry analysis of blood collected 24 hours after the bead injection demonstrated efficient 
labeling of circulating monocytes consistent with previous reports (Fig S8b,c)32-34. Importantly, there 
were no changes in blood cell populations after the bead and antibody treatment (Fig S8d). BCA 
plaques from IL-ȕantibody and IgG control treated mice showed no differences in bead accumulation 
(Fig 4b,c). However, IL-ȕantibody treated mice exhibited a marked decrease in the ratio of beads to 
0ĭ (Fig 4c), suggesting that the 0ĭ accumulation induced by IL-ȕLQKLELWLRQwas not due to an 
increase in newly recruited monocytes. 
7RGHWHUPLQHLIWKHDFFXPXODWLRQRI0ĭZDVGULYHQE\SUROLIHUDWLRQZHSHUIRUPHG
immunostaining for Ki67 on mice treated with 3 weeks of IL-ȕ antibody or IgG control (Fig 4d). 
Although the overall fraction of proliferating cells was not significantly changed (Fig 4e), treatment with 
the IL-ȕDQWLERG\SURIRXQGO\changed which cell types underwent proliferation in the fibrous cap. 
Specifically, there was marked reduction in YFP+ SMC proliferation and an increase in 0ĭ (YFP-
LGALS3+) proliferation (Fig 4e,f). However, there was no change in the proliferation of YFP+LGALS3+ 
cells indicating that the exacerbation of LGALS3+ proliferation did not include SMC-derived 0ĭ-like 
cells (Fig 4f). Of note, IL-ȕLQKLELWLRQGLGQRWLQGXFHFKDQJHVLQHQGRWKHOLDOFHOOSUROLIHUDWLRQFig S9). 
We also assessed the proportion of YFP+ and LGALS3+ cells undergoing apoptosis in these same 
samples. TUNEL (Fig 4g,h) and cleaved Caspase3 (Fig S10) analyses showed no differences in 
apoptosis of 60&RU0ĭLQ,/-ȕDQWLERG\WUHDWHGPLFHDVFRPSDUHGWRFRQWUROV Taken together, these 
data show that inhibition of IL-ȕSURIRXQGO\LPSacts the cell composition within advanced 
atherosclerotic plaques primarily by inhibiting SMC proliferation and promoting proliferation of 0ĭ 
within lesions. 
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IL-1 signaling is required for SMC investment into lesions and the fibrous cap 
The preceding observations demonstrate that inhibition of IL-ȕin mice with advanced lesions 
resulted in a dramatic reduction in SMC and increase in 0ĭ within the fibrous cap. However, it is 
unclear if these changes were mediated via direct loss of IL-1 signaling in SMC, 0ĭ, or other cell types 
within the lesions. Although there is extensive evidence that IL-ȕpromotes atherosclerosis 
development 14-16 and that non-myeloid cells play a key role 22,23, the relative contribution of IL1 
signaling in SMC versus 0ĭ in this process is unknown.   
Thus, to ascertain the role of IL-1 signaling in SMC on atherosclerosis development, we 
generated mice with tamoxifen-inducible SMC-specific Il1r1 KO and simultaneous SMC lineage tracing 
by crossing Il1r1fl/fl mice 35 with Apoe-/- Myh11 Cre ERT2 R26R-YFP mice (Fig S11a). The resulting 
Apoe-/- Myh11 Cre ERT2 R26R-YFP Il1r1fl/fl and littermate control Il1r1WT/WT mice were treated with a 
series of tamoxifen injections from 6 to 8 weeks of age to induce simultaneous expression of a YFP 
lineage tracing gene, and excision of exon 5 of the Il1r1 gene exclusively in SMC 8,28 (designated below 
as Il1r1SMC ǻǻ or Il1r1SMC WT/WT) before being fed a WD for 18 weeks (Fig S11b). We observed high 
efficiency recombination of Il1r1 in SMC rich tissues including aorta, carotid, and lung in tamoxifen-
treated Il1r1SMC fl/fl mice (Fig S11c). Importantly, there was no detectable Il1r1 recombination in Il1r1SMC 
fl/fl
 without tamoxifen, or in tamoxifen-treated Il1r1SMC WT/WT control mice. In addition, recombination of 
the Il1r1 locus was associated with corresponding reductions in IL-1R1 protein expression based on 
immunohistochemical staining of carotid medial SMC in Il1r160&ǻǻ mice with an anti-IL-1R1 antibody 
(Fig S11d).  There were no significant differences in body weight or serum cholesterol and triglyceride 
levels (Fig S11e-f).  However, remarkably, we observed a >60% reduction in BCA plaque size in 
Il1r160&ǻǻ mice as compared to Il1r1SMC WT/WT mice (Fig 5a,b), as well as a marked reduction in 
collagen content (Fig 5c,d) but no difference in intraplaque hemorrhage (Fig 5e,f). Of major interest, 
the lesions in the Il1r160&ǻǻ mice were almost entirely devoid of SMC (YFP+) and ACTA2+ cells, but 
significantly enriched in YFP- LGALS3+ cells (Fig 5g-i). This was particularly evident in the fibrous cap 
area which exhibited an >80% reduction in YFP+ area and a 70% decrease in ACTA2+ area. In addition, 
fibrous cap areas from Il1r160&ǻǻ mice had a 2.8 fold increase in LGALS3+ area (Fig 5i).  
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We also tested the effect of 0ĭ-selective Il1r1-/- on atherosclerosis development using Apoe-/- 
LysM Cre R26R-YFP Il1r1fl/fl and Apoe-/- LysM Cre R26R-YFP Il1r1WT/WT littermate control mice fed WD 
for 18 weeks (Fig S12a,b). Importantly, this LysM Cre gene targeting results in efficient gene targeting 
of monocytes, mature macrophages and granulocytes 36. LysM cre driven knockout of IL1R1 induced a 
complete inhibition of the IL-1 signaling pathway as demonstrated by the lack of IRAK phosphorylation 
in LGALS3+YFP+ cells within atherosclerotic lesions of Il1r10ĭ ǻǻ (Fig S12e). In contrast to the profound 
effects of SMC-specific Il1r1 deletion, there was no significant effect of losing IL-1R1 in LysM 
expressing cells on vessel size, lesion size, or the frequency of YFP+, LGALS3+, or ACTA2+ cells (Fig 
S13). Taken together, these cell-specific Il1r1 KO studies provide compelling evidence that IL-1 
signaling in SMC, rather than myeloid cells, plays a critical role during atherosclerosis development. 
Moreover, results suggest that the reductions in indices of plaque stability observed in our IL-ȕ
neutralization experiments, including the marked loss of SMC and collagen, as well as increases in 0ĭ 
within the fibrous cap, are due, at least in part, to disrupted IL-1 signaling in SMC. 
 
IL-ȕneutralization increased IL-4 levels and promoted macrophage M2 polarization  
To determine potential mechanisms altering the cellular composition of the fibrous cap following 
IL-1ȕ antibody treatment, we performed a cytokine and chemokine array on BCA tissue extracts from 
mice treated with 8 weeks of either IL-1ȕ or control antibody (Fig 6a). Interestingly, there was a two-fold 
increase in IL-4 protein in BCA lesions from the IL-1ȕ antibody treated mice. Of interest, IL-4 has been 
shown to inhibit SMC 37,38 but promote resident 0ĭ proliferation 39,40, consistent with our in vivo Ki67 
staining data showing profound inhibition of SMC proliferation but stimulation of 0ĭ proliferation (Fig 
4). IL-4 has also been identified as a key cytokine involved in M2 polarization of 0ĭ in vitro 41,42. To 
better understand the impact of IL-1ȕ neutralization on macrophage phenotype, we performed staining 
for classic M1 (iNOS) and M2 (Arg-1) markers. Although there are considerable limitations to the 
M1/M2 paradigm in vivo, confocal analyses of these markers provide the spatial resolution required to 
study individual cells within the fibrous cap area as well as critical insights into the possible function of 
the accumulated macrophages. Consistent with the increased IL-4, there was a decrease in the number 
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of LGALS3+iNOS+ , but a large increase in Arg-1+ expression in macrophages within the fibrous cap 
area (Fig 6b,c). These results suggest that IL-ȕ neutralization induces an anti-inflammatory 
SKHQRW\SHLQWKHUHVLGHQW0ĭSRSXODWLRQZLWKLQWKHILEURXVFDSthat is mediated, at least in part, by 
increased IL-4.  
 
 
 
Discussion 
Our present study provides compelling evidence of a critical role for IL-1 signaling during late-
stage atherosclerosis. However, contrary to our expectations, IL-1 signaling appeared to play multiple 
beneficial roles that were inhibited following either IL-1ȕ neutralization or specific loss of Il1r1 in SMC. 
Indeed, we found that IL-1 signaling in SMC was required for SMC investment into lesions and for the 
formation of a SMC-rich, collagen-rich fibrous cap. That is, although lesions from SMC-specific Il1r1 KO 
Apoe-/- mice were smaller, they exhibited a number of changes believed to be detrimental  including a 
failure to form a protective ACTA2+ fibrous cap, a reduction in collagen content, and an enrichment in 
macrophage content. Moreover, consistent with these findings, IL-ȕ antibody treatment of SMC 
lineage tracing Apoe-/- mice with advanced atherosclerosis, for 3 or 8 weeks, resulted in marked 
reductions in a number of plaque stability indices. These changes included a 40% decrease in SMC 
content, a >50% decrease in ACTA2+ coverage, a 30% reduction in collagen content, and a 50% 
increase in 0ĭ (M2) content within the fibrous cap. Taken together, these observations have several 
important implications for the atherosclerosis field. First, our results indicate an unexpected role for IL-
1ȕin regulating fibrous cap formation in advanced lesions and suggest that excessive inhibition of 
inflammation could potentially have detrimental effects. Indeed, Tabas and co-workers have long 
emphasized the importance of improving inflammation resolution, rather than suppression, as a key 
therapeutic approach for attempting to stabilize lesions 11,43,44. Second, the fibrous cap is far more 
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plastic than anticipated, a finding that if true in humans, may have important implications for 
atherosclerotic disease management and development of more effective therapeutic approaches. 
Third, our results highlight the need for increased emphasis on intervention rather than prevention 
models in preclinical studies that are attempting to identify therapeutic agents that will benefit patients 
with advanced atherosclerosis 27. The importance of this concept is made particularly clear when 
comparing a previous prevention study that treated Apoe-/- mice from the beginning of WD feeding with 
an IL-1ȕ neutralizing antibody and showed reduced plaque formation 17, with our intervention study that 
showed no improvement on the same measurement but revealed changes consistent with plaque 
destabilization. Therefore, one cannot assume that pharmacological agents that are effective at 
preventing fatty streak formation in young animals when treatment is initiated prior to lesion 
development will necessarily have beneficial effects in the setting of established atherosclerosis. 
 
One of the most striking observations following IL-ȕ neutralization in advanced lesions was the 
loss of SMC within the fibrous cap. Our data suggest this is driven by reduced SMC proliferation, which 
is consistent with previous studies demonstrating that IL-ȕLVDSRWHQWLQGXFHURI60&SUROLIHUDWLRQ in 
vitro 25,26. Although reduced SMC proliferation after 3 weeks of treatment may be responsible for the 
overall reduction in SMC number seen with 8 weeks of treatment, another likely mechanism is impaired 
migration and/or homing of SMC into the fibrous cap. One possible mechanism involved in the cellular 
redistribution would be changes in the production or sensitivity to guidance cues. Consistent with this 
possibility, Moore and co-workers 45,46 have identified several 0ĭ chemo-attractant and chemo-
repulsive proteins whose production by SMC could be regulated by IL-1ȕ.   
 
The loss of SMC occurred in conjunction with an increase in the number of 0ĭafter just 3 
weeks of IL-ȕDQWLERG\treatment. Interestingly, the accumulation of 0ĭ within the lesions was 
restricted to YFP-LGALS3+ cells. While SMC-derived 0ĭ-like cells (YFP+LGALS3+) were present in the 
fibrous cap of both IL-ȕDQWLERG\DQG,J*FRQWUROWUHDWHGPLFHWKHLUQXPEHUs were unchanged by 
treatment. Importantly, accumulation of 0ĭwas driven by increased local proliferation of resident 0ĭ 
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rather than increased monocyte recruitment from the bone marrow. These observations are consistent 
with studies by Swirski and co-workers 47 showing that proliferation of resident 0ĭ, rather than 
increased monocyte trafficking, regulates 0ĭ expansion in established lesions. However, our studies 
are the first to show that this is a function of IL-ȕ and that its neutralization appears to promote M2 
polarization and proliferation. These effects could be due to a direct effect of inhibiting IL-1 signaling in 
0ĭ. However, due to the complete lack of a phenotype in the 0ĭ-selective Il1r1 KO studies, it likely 
involves a different pathway. 
 
Of interest, we present correlative evidence suggesting that increased expression of IL-4 may 
contribute to reduced proliferation of SMC while simultaneously stimulating proliferation of resident 0ĭ
as well as their M2 polarization. Indeed, consistent with this possibility, IL-4 has previously been shown 
to induce these changes in cultured SMC and macrophages respectively 37,39,40. Although 00ĭKDYH
been shown to play a beneficial role in atherosclerosis pathogenesis, it remains to be determined 
whether an influx of M2 or M2-like 0ĭ into the fibrous cap would be beneficial or detrimental for lesion 
stability. However, our results suggest that this may be detrimental due to the loss of SMC and 
collagen, and that IL-1ȕ inhibition may be associated with a false sense of inflammation resolution. 
Specifically, the global decrease in pro-inflammatory pathways measured by RNA-seq and the 
enrichment in anti-inflammatory-like macrophages occurs despite failure to resolve the necrotic core, 
reduce the extent of intraplaque hemorrhage or calcification, or to clear plaque cholesterol crystals48. 
This false-sense of inflammation resolution may also apply to SMC that appear to rely on IL-1ȕ 
stimulation to form a SMC/collagen-rich fibrous cap. Indeed, several in vitro studies have shown that IL-
ȕSRWHQWly induces SMC proliferation 25, promotes matrix metalloproteinase 3 (MMP3)-dependent SMC 
migration 31, and markedly induces SMC collagen synthesis 30, which are all processes that would be 
critical for maintaining a fibrous cap. In addition, global Il1r1 deletion was associated with reduced 
collagen content and loss of an ACTA2+ fibrous cap in advanced atherosclerotic lesions 31. Finally, 
although excessive inflammation has been clearly linked with increased risk of cardiovascular disease 
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49,50
, there may be an ideal level of inflammation inhibition that supports the beneficial processes 
induced by IL-ȕ while suppressing the detrimental processes (e.g., endothelial cell activation).  
 
A critical question is to determine to what extent, if any, our IL-ȕantibody intervention studies 
in mice translate to patients, including those in large anti-inflammatory atherosclerosis clinical trials, 
and, most importantly, the Novartis-sponsored CANTOS (Canakinumab Anti-inflammatory Thrombosis 
Outcomes Study) Phase III Clinical Trial that was recently completed 20. This trial enrolled over 10,000 
patients who were treated with canakinumab at three different dosages (50, 150, and 300mg) or 
placebo and tracked over a median period of 3.7 years. Importantly, CANTOS enrolled a unique patient 
population that is at very high risk for future cardiovascular events (>4.50 events per 100 person-
years). Specifically, each patient had already survived at least one MI and had elevated biomarkers of 
LQIODPPDWLRQKV&53PJ/despite standard of care therapy including high-intensity statin therapy in 
most cases 19. Of major significance for the cardiovascular field, CANTOS met its primary endpoint of 
reducing a composite of nonfatal MI, nonfatal stroke, and cardiovascular death20,21 thus providing the 
most direct evidence to date validating the inflammation hypothesis of atherosclerosis in man, and 
achieving a reduction in cardiovascular risk via a therapy independent of lipid lowering (see editorials 
by us51 and others52,53). However, it is critical to appreciate that: 1) CANTOS met its primary endpoint 
only at the intermediate of three dosages tested; 2) there was no benefit on all cause or cardiovascular 
mortality; and 3) there was a 40% increase in death due to lethal infection20. Importantly, a subsequent 
CANTOS report showed a 31% reduction in CV mortality and all-cause mortality in the subset of 
CANTOS subjects who achieved on-treatment hsCRP levels of <2.0mg/L versus no effect in subjects 
whose hsSRP >2mg/L21. These latter results are quite exciting in that they indicate that Canakinumab 
may be an appropriate therapy, at least for this subset of very high risk post-MI normolipidimic patients, 
but would seem to be at complete odds with our findings that IL-1E antibody treatment of Apoe-/- mice 
with advanced lesions resulted in rapid loss of SMC and collagen within the fibrous cap (Figures 2-3).  
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However, there are major limitations in directly comparing the results of our mouse intervention 
studies with the outcome of the CANTOS Trial. First, there are inherent differences between humans 
and mice that confound direct translation of our results to clinical trials. These include differences in 
disease time-course (i.e., weeks in mice versus decades in humans), fundamental differences in the 
immune system, a lack of genetic diversity in mice, and much higher lipid levels in Apoe-/- mice which is 
necessary for lesion formation 54. In addition, >80% of CANTOS subjects had a percutaneous coronary 
intervention or coronary bypass; >90% were taking antithrombotic, lipid-lowering, and/or anti-ischemic 
agents; and >79% were on inhibitors of the renin-angiotensin system. Second, it is possible that we are 
modeling fundamentally different mechanisms than those operative in CANTOS patients including 
effects of a prior MI that was not a component of our experimental design. Third, there are several 
studies reporting improved glycemic control and insulin sensitivity with inhibition of IL-1 signaling 10,55,56. 
Therefore, patients treated for 3-5 years with canakinumab are likely to have long-term benefits on 
metabolic parameters as well as a reduction in microvascular inflammation and dysfunction, which are 
unlikely to be evident in our relatively short murine intervention studies. Fourth, the IL-1E antibody 
dosing regimens are very different between our mouse (weekly) and the CANTOS human (quarterly) 
studies due at least in part to the half-life of Canakinumab being over twice as long (27 days) as the 
mouse IL-1Eantibody (12 days). However, we feel this is unlikely to be the key driver of the surprising 
effects given that we observed very similar effects with a ten-fold lower dose (1mg/kg) of the IL-1E 
antibody in our mouse studies, suggesting that our results are not a function of an overly aggressive 
dosing strategy and/or due to excessive suppression of IL1E. That being said, the results of CANTOS 
clearly show that the clinical benefit of canakinumab in reducing all-cause and cardiovascular mortality 
is highly dependent on the response of an individual patient to a given dosage, and more specifically to 
the degree of hsCRP lowering. The implication is that there may be a very narrow window where 
canakinumab is both effective and safe for a given patient especially given the marked increase in 
lethal infections among patients treated with canakinumab. Fifth, our mice are severely 
hypercholesterolemic whereas the CANTOS patients had relatively well managed cholesterol levels 
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(e.g., LDL cholesterol <83mg/dL). As such, our model in hypercholesterolemic mice most closely 
emulates cholesterol-driven plaque rupture events and our indices of lesion stability are derived from 
histological features of thin-capped fibroatheromas (plaques most vulnerable to rupture). However, it is 
possible that the CANTOS patients are more at risk for plaque erosion, rather than rupture, events. 
Indeed, CANTOS patients had been treated aggressively with lipid lowering agents (e.g., high-intensity 
statin treatment) in addition to canakinumab and had relatively well-controlled cholesterol levels. As 
such the current thought is that these patients have reduced plaque lipid content and are at greater risk 
for plaque erosion events 57, which our model poorly replicates. Unfortunately, the CANTOS trial did not 
differentiate non-ST elevation MI (more associated with plaque erosion) versus ST-elevation MI (more 
associated with plaque rupture). 
 
Despite these limitations, our results provide novel insights as to how global suppression of IL1E 
impacts the composition of advanced lesions, may help explain why canakinumab treatment did not 
benefit the majority of patients treated, and/or may help to identify patients who might be harmed by 
this treatment. Indeed, our results remind us that inflammatory processes evolved to protect the host 
and that great care should be applied when targeting these pathways. A major challenge moving 
forward will be to determine to what extent canakinumab or other broadly acting anti-inflammatory 
agents should be extended to lower-risk patients. Specifically, it will be critical to determine strategies to 
identify subsets of patients that will exhibit the most benefit from these therapies, and perhaps more 
importantly to determine if there are patients that may be more susceptible to the adverse effects. In 
support of this hypothesis, two clinical studies are consistent with our findings and suggest that 
inhibition of IL-1 signaling may unexpectedly increase the risk of some cardiovascular events. First, the 
MRC-ILA Heart Study was a Phase IIb, double-blinded, randomized, placebo-controlled study of 
Anakinra, a recombinant IL-1 receptor antagonist (IL-1ra), administered for two weeks to patients 
following a non-ST elevation MI 58. Although not powered to measure long-term outcomes, the study 
showed that Anakinra treatment increased major adverse cardiovascular events, including MI, at one 
year by greater than four-fold. Second, studies by the IL-1 Genetics Consortium 59 investigated two 
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common variants located upstream of the IL-1ra locus known to increase its expression. This 
retrospective study of 746,171 patients showed that increased levels of IL-1ra are correlated with 
reduced hs-CRP and IL-6, consistent with reduced systemic inflammation, but with an allele-dependent 
increase in coronary artery disease. As such, we believe the greatest value of our late-stage 
atherosclerosis intervention studies in mice is to generate hypotheses, which might be tested in man to 
better understand the mechanistic and physiological aspects of IL-ȕ inhibition. In addition, armed with 
a greater understanding of the basic vascular biology, the field can identify alternative (or combinatorial) 
anti-inflammatory therapeutic targets that are both effective and safe for treating a broader and lower 
risk cohort of human subjects.  
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Figure Legends 
 
Figure 1: IL-ȕDQWLERG\ treatment resulted in systemic and local downregulation of the IL-1 
signaling and pro-inflammatory pathways.  
a – Schematic of intervention studies during which Apoe-/- Myh11 ERT2 Cre YFP mice fed a WD for 18 
weeks were injected weekly with the IL-ȕDQWLERG\RUan isotype-matched IgG control antibody at a 
concentration of 10mg/kg for 8 weeks. Assessment of systemic inflammation by quantification of 
plasma Serum Amyloid A (b) and IL-ȕLQSODVPDDQGOLYHUb) (n=12 per group). Data were analyzed 
with a non-parametric Mann-Whitney U-test (b and c) and presented as the mean ± SEM. d – Results 
of RNA-seq analyses on tissue extracts from the BCA of IL-ȕDQWLERG\DQG,J*FRQWURO treated mice 
(n=4 per group). Pathway-enrichment charts display pathways that were downregulated or upregulated 
in IL-ȕDQWLERG\WUHDWHGPLFHDVFRPSDUHGWRIgG control treated mice. The red lines indicate results 
are significant with an adjusted P value of Padj (QULFKPHQWis shown as the ílog10 of Padj values. 
Underlined pathways are related to immunity and inflammation. e – Pie charts show functional 
annotation analyses of pathways downregulated (upper pie charts) or upregulated (bottom pie chart) in 
BCA extracts of IL-ȕDQWLERG\WUHDWHGPLFHDVFRPSDUHGWRFRQWURODVGHWHUPLQHGE\51$VHT
analysis. f – Representative images of phospho-IRAK and IL-6 immunostaining in BCA sections of IgG 
control and IL-ȕDQWLERG\WUHDWHGPLFH6FDOHEDU100 µm. g – Quantification of phospho-IRAK and 
IL6 staining by integrated optical densitometry analysis. Data were analyzed by an unpaired t-test and 
presented as the mean ± SEM.  
 
Figure 2: IL-1ȕ inhibition induced multiple detrimental changes in the pathogenesis of late stage 
atherosclerotic lesions including loss of SMC-rich fibrous cap and inhibition of beneficial 
outward remodeling.  
a – Sudan IV staining of aortic plaque burden. b – Quantification of Sudan IV positive area (n=6). c - 
Representative images of Movat stained BCA sections. d – Vessel, lesion and lumen area of BCA 
cross-sections from 18 week WD fed, 26 week WD fed IgG control treated, and 26 week WD fed IL-ȕ
antibody treated Apoe-/- Myh11 ERT2 Cre YFP mice (n=10 per group). e – Representative pictures 
showing modifications in the distribution of YFP+, LGALS3+, and ACTA2+ cells in the fibrous cap area of 
mice treated with the IL-ȕDQWLERG\DQG,J*FRQWURO f – Quantification of YFP+ and YFP+ACTA2+ cells 
normalized to the total number of cells within the fibrous cap area. g – Quantification of YFP-LGALS3+ 
and YFP+LGALS3+ cells normalized to the total number of cells within the fibrous cap area. h – 
Proportion of YFP+LGALS3+ normalized to the SMC YFP+ population within the fibrous cap. i – Fibrous 
cap thickness (µm) as determined by the average thickness of ACTA2+ cells from the endothelial layer. 
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Data were analyzed by an unpaired t-test (b, d, f-i) and presented as the mean ± SEM. Scale bar, 100 
µm (c, e). 
 
Figure 3:  Three-week IL-ȕantibody treatment resulted in an increased number of 
macrophages within the fibrous cap.  
a – Schematic of short-term treatment of Apoe -/- Myh11 ERT2 Cre YFP fed a WD for 18 weeks with 
weekly injections with IL-ȕRU,J*FRQWUROantibodies at a concentration of 10 mg/kg for 3 weeks (n=8). 
b – Representative images of the modified distribution of YFP+, LGALS3+, and ACTA2+ cells following 3 
weeks of treatment with the IL-ȕDQWLERG\. Scale bar, 100 µm. c – Proportion of YFP+, LGALS3+ and 
ACTA2+ cells normalized to the total number of cells within the fibrous cap area. d – Number of cells 
normalized to the area of the fibrous cap (µm2). e – Quantification of YFP-LGALS3+ cells versus 
YFP+LGALS3- cells within the fibrous cap. Data were analyzed by unpaired t-test (c-e) and presented 
as the mean ± SEM. 
 
Figure 4: IL-ȕLQKLELWLRQ for three-weeks resulted in increased proliferation of local 
macrophages but no change in monocyte trafficking or apoptosis.  
a – Schematic representing the experimental design of bead uptake assays performed in Apoe-/- Myh11 
ERT2 Cre YFP mice treated with IL-ȕDQWLERG\RU,J*FRQWUROB) Representative images of bead 
uptake within the BCA lesions stained for LGALS3+ and visualizing Cy3-labeled beads. (C) 
Quantification of bead uptake with the total number of beads per section (left) and the number of beads 
normalized to the number of LGALS3+ cells (n=5). (D) Assessment of cell proliferation and 
representative images of staining for YFP, ACTA2, LGALS3 and Ki67 in BCA sections of IL-ȕDQWLERG\
treated and control mice. (E) Quantification of Ki67+ cells and Ki67+ subpopulations (Ki67+YFP+ and 
Ki67+LGALS3+; n=6). Data were analyzed using an unpaired t-test (E) and a non-parametric Mann-
Whitney U-test (C) and presented as average ± SEM. Scale bar, 100 µm (B & D). 
 
Figure 5: IL-1 signaling within SMC was required for SMC investment into the lesion and the 
fibrous cap.  
a – Movat staining of BCA sections from Il1r1SMC WT/WT and Il1r160&ǻǻ littermates fed a WD for 18 
weeks. b – Morphometric analysis of the vessel, lesion, and lumen area of Il1r1SMC WT/WT and Il1r160&ǻǻ 
BCA cross-sections (n = 12 per group). c – Representative images of Picrosirius Red staining 
(polarized light). d – Collagen content quantification expressed as a percentage of lesion area (n = 8 
per group). e – Representative images of Ter119 staining used to detect intraplaque hemorrhage. f – 
Distribution of intraplaque hemorrhage positive and negative lesions in Il1r1SMC WT/WT and Il1r160&ǻǻ 
mice.  g – Immunofluorescent staining of BCA sections from Il1r1SMC WT/WT and Il1r160&ǻǻ mice for YFP, 
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ACTA2 and LGALS3. A high magnification image of the fibrous cap is delineated by a dashed line. h-i – 
Pixel quantification of YFP+, ACTA2+, and LGALS3+ areas normalized to the lesion area (h) and the 
30µm fibrous cap area (i) (n = 12 per group). Data were analyzed with an unpaired t-test (b,d), an exact 
Fisher test (f), or a non-parametric Mann-Whitney U-test (h,i) and presented as the mean ± SEM. Scale 
bar, 100 µm (a,c,e,g). 
 
Figure 6: IL-ȕLQKLELWLRQwas associated with polarization of fibrous cap macrophages to an M2 
phenotype. a – A cytokine and chemokine array was performed on protein extracts from BCA of mice 
treated with IL-ȕDQWLERG\IRU8 weeks as compared to control (n=5 per group). Protein abundance of 
monocyte and macrophage colony stimulating factors (CSF2 and CSF3), monocyte chemoattractant 
CCL2, pro-inflammatory cytokine IL-6 and anti-inflammatory cytokines IL-10 and IL-4 are shown. b – 
Quantification of the number of LGALS3+iNOS+ and LGALS3+Arg-1+ cells normalized to DAPI or the 
total number of LGALS3+ cells in BCA lesions of mice treated for 3 weeks with the IL-ȕDQWLERG\RU
IgG control (n=6 per group). c – Representative images of immunostaining for ACTA2, LGALS3, M1 
marker iNOS (upper panels) or M2 marker Arg-1 (lower panels). Scale bar, 100 µm. Data were 
analyzed using an unpaired t-test (a,b) or non-parametric Mann-Whitney U-test (b) and presented as 
the mean ± SEM.  
 
 
 
 
 
 
 
 
 
 






